Beam Therapeutics Inc. Income Statement
BEAM / Health Care|7 years of annual SEC 10-K data (FY2019-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 7 fiscal years. All figures from audited SEC 10-K filings.
Beam Therapeutics Inc. reported $140M in revenue and $80M in net loss for FY2025. Revenue has grown at a 345.0% compound annual rate over the past 6 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 1.06 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $139.7M | $63.5M | $377.7M | $60.9M | $51.8M | $18.0K | $18.0K |
| SG&A Expense | $113.8M | $111.5M | $116.8M | $87.8M | $57.2M | $20.6M | $20.6M |
| R&D Expense | $409.6M | $367.6M | $437.4M | $311.6M | $387.1M | $54.6M | $54.6M |
| Operating Income | -$383.7M | -$415.6M | -$176.5M | -$338.5M | -$392.5M | -$75.2M | -$75.2M |
| Income Tax | $0 | $39.0K | $1.4M | $3.4M | $0 | $0 | $0 |
| Net Income | -$80.0M | -$376.7M | -$132.5M | -$289.1M | -$370.6M | -$78.3M | -$78.3M |
| EPS (Basic) | -$0.81 | -$4.58 | -$1.72 | -$4.13 | -$5.77 | - | -$14.05 |
| EPS (Diluted) | -$0.81 | -$4.58 | -$1.72 | -$4.13 | -$5.77 | -$14.05 | -$14.05 |
| Shares Outstanding | 101.7M | 83.6M | 81.6M | 71.3M | 68.4M | 7.3M | 6.5M |
| Operating Margin | -274.6% | -654.3% | -46.7% | -555.6% | -757.0% | -417522.2% | - |
| Profit Margin | -57.2% | -593.1% | -35.1% | -474.5% | -714.9% | -435144.4% | - |